Literature DB >> 21477676

Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine.

Catherine Yen1, Kathleen Jakob, Mathew D Esona, Ximara Peckham, John Rausch, Jennifer J Hull, Susan Whittier, Jon R Gentsch, Philip LaRussa.   

Abstract

Studies on rotavirus vaccine shedding and its potential transmission within households including immunocompromised individuals are needed to better define the potential risks and benefits of vaccination. We examined fecal shedding of pentavalent rotavirus vaccine (RV5) for 9 days following the first dose of vaccine in infants between 6 and 12 weeks of age. Rotavirus antigen was detected by enzyme immunoassay (EIA), and vaccine-type rotavirus was identified by nucleotide sequencing based on genetic relatedness to the RV5 VP6 gene. Stool from 22 (21.4%) of 103 children contained rotavirus antigen-positive specimens on ≥ 1 post-vaccination days. Rotavirus antigen was detected as early as post-vaccination day 3 and as late as day 9, with peak numbers of shedding on post-vaccination days 6 through 8. Vaccine-type rotavirus was detected in all 50 antigen-positive specimens and 8 of 8 antigen-negative specimens. Nine (75%) of 12 EIA-positive and 1 EIA-negative samples tested culture-positive for vaccine-type rotavirus. Fecal shedding of rotavirus vaccine virus after the first dose of RV5 occurred over a wide range of post-vaccination days not previously studied. These findings will help better define the potential for horizontal transmission of vaccine virus among immunocompromised household contacts of vaccinated infants for future studies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21477676      PMCID: PMC4459210          DOI: 10.1016/j.vaccine.2011.03.074

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Authors:  Timo Vesikari; David O Matson; Penelope Dennehy; Pierre Van Damme; Mathuram Santosham; Zoe Rodriguez; Michael J Dallas; Joseph F Heyse; Michelle G Goveia; Steven B Black; Henry R Shinefield; Celia D C Christie; Samuli Ylitalo; Robbin F Itzler; Michele L Coia; Matthew T Onorato; Ben A Adeyi; Gary S Marshall; Leif Gothefors; Dirk Campens; Aino Karvonen; James P Watt; Katherine L O'Brien; Mark J DiNubile; H Fred Clark; John W Boslego; Paul A Offit; Penny M Heaton
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

2.  Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency.

Authors:  Rebecca L Werther; Nigel W Crawford; Karen Boniface; Carl D Kirkwood; Joanne M Smart
Journal:  J Allergy Clin Immunol       Date:  2009-08-05       Impact factor: 10.793

3.  Efficiency of human rotavirus propagation in cell culture.

Authors:  R L Ward; D R Knowlton; M J Pierce
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

4.  Rotavirus infections in paediatric oncology patients: a matched-pairs analysis.

Authors:  Amnna Rayani; Udo Bode; Elmukhtar Habas; Gudrun Fleischhack; Steffen Engelhart; Martin Exner; Oliver Schildgen; Gabi Bierbaum; Anna Maria Eis-Hübinger; Arne Simon
Journal:  Scand J Gastroenterol       Date:  2007-01       Impact factor: 2.423

5.  Sequence analysis of the VP4, VP6, VP7, and NSP4 gene products of the bovine rotavirus WC3.

Authors:  Max Ciarlet; Joseph M Hyser; Mary K Estes
Journal:  Virus Genes       Date:  2002-03       Impact factor: 2.332

6.  Clinical features of nosocomial rotavirus infection in pediatric liver transplant recipients.

Authors:  S W Fitts; M Green; J Reyes; B Nour; A G Tzakis; S A Kocoshis
Journal:  Clin Transplant       Date:  1995-06       Impact factor: 2.863

7.  Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance.

Authors:  A Z Kapikian; R G Wyatt; M M Levine; R H Yolken; D H VanKirk; R Dolin; H B Greenberg; R M Chanock
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

8.  Identification of group A rotavirus gene 4 types by polymerase chain reaction.

Authors:  J R Gentsch; R I Glass; P Woods; V Gouvea; M Gorziglia; J Flores; B K Das; M K Bhan
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

9.  Chronic rotavirus infection in immunodeficiency.

Authors:  F T Saulsbury; J A Winkelstein; R H Yolken
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

10.  Enhancement of detection and quantification of rotavirus in stool using a modified real-time RT-PCR assay.

Authors:  Molly M Freeman; Tara Kerin; Jennifer Hull; Karen McCaustland; Jon Gentsch
Journal:  J Med Virol       Date:  2008-08       Impact factor: 2.327

View more
  19 in total

1.  Rotavirus VP7 epitope chimeric proteins elicit cross-immunoreactivity in guinea pigs.

Authors:  Bingxin Zhao; Xiaoxia Pan; Yumei Teng; Wenyue Xia; Jing Wang; Yuling Wen; Yuanding Chen
Journal:  Virol Sin       Date:  2015-10-10       Impact factor: 4.327

2.  Monitoring Shedding of Five Genotypes of RotaTeq Vaccine Viruses by Genotype-Specific Real-Time Reverse Transcription-PCR Assays.

Authors:  Yuki Higashimoto; Masaru Ihira; Yu Miyazaki; Ayumi Kuboshiki; Sayaka Yoshinaga; Hiroyuki Hiramatsu; Ryota Suzuki; Masafumi Miyata; Hiroki Miura; Satoshi Komoto; Jun Yukitake; Koki Taniguchi; Yoshiki Kawamura; Tetsushi Yoshikawa
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

3.  Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine.

Authors:  Daniel Cowley; Karen Boniface; Nada Bogdanovic-Sakran; Carl D Kirkwood; Julie E Bines
Journal:  Hum Vaccin Immunother       Date:  2017-05-08       Impact factor: 3.452

4.  Symptomatic infection and detection of vaccine and vaccine-reassortant rotavirus strains in 5 children: a case series.

Authors:  Julie A Boom; Leila C Sahni; Daniel C Payne; Rashi Gautam; Freda Lyde; Slavica Mijatovic-Rustempasic; Michael D Bowen; Jacqueline E Tate; Marcia A Rench; Jon R Gentsch; Umesh D Parashar; Carol J Baker
Journal:  J Infect Dis       Date:  2012-08-07       Impact factor: 5.226

5.  Vaccine-derived NSP2 segment in rotaviruses from vaccinated children with gastroenteritis in Nicaragua.

Authors:  Filemón Bucardo; Christine M Rippinger; Lennart Svensson; John T Patton
Journal:  Infect Genet Evol       Date:  2012-04-02       Impact factor: 3.342

6.  One-step Quantitative RT-PCR Assays for Detecting, Genotyping and Differentiating Wild-Type Group a Rotaviruses and Vaccine (Rotarix® and RotaTeq®) Strains in Stool Samples.

Authors:  Rashi Gautam; Michael D Bowen
Journal:  J Vaccines Vaccin       Date:  2016-09-26

7.  Detection of PCV-2 DNA in stool samples from infants vaccinated with RotaTeq®.

Authors:  Mathew D Esona; Slavica Mijatovic-Rustempasic; Catherine Yen; Umesh D Parashar; Jon R Gentsch; Michael D Bowen; Philip LaRussa
Journal:  Hum Vaccin Immunother       Date:  2013-10-08       Impact factor: 3.452

8.  Influenza virus detection in the stool of children with acute gastroenteritis.

Authors:  Jianling Xie; Xiao-Li Pang; Gillian A M Tarr; Yuan Mu; Ran Zhuo; Linda Chui; Bonita E Lee; Otto G Vanderkooi; Phillip I Tarr; Samina Ali; Shannon E MacDonald; Stephen B Freedman
Journal:  J Clin Virol       Date:  2020-08-01       Impact factor: 3.168

9.  Low prevalence of rotavirus and high prevalence of norovirus in hospital and community wastewater after introduction of rotavirus vaccine in Nicaragua.

Authors:  Filemón Bucardo; Per-Eric Lindgren; Lennart Svensson; Johan Nordgren
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

10.  Real-time RT-PCR assays to differentiate wild-type group A rotavirus strains from Rotarix(®) and RotaTeq(®) vaccine strains in stool samples.

Authors:  Rashi Gautam; Mathew D Esona; Slavica Mijatovic-Rustempasic; Ka Ian Tam; Jon R Gentsch; Michael D Bowen
Journal:  Hum Vaccin Immunother       Date:  2013-12-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.